Streetbeat News

Regulatory

MULN

Mullen Automotive has regained full compliance with Nasdaq's listing requirements, leading to the cancellation of a previously scheduled panel hearing. The company will continue its listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:03 pm

AMLX

Amylyx Pharmaceuticals announced positive topline results from its Phase 2 HELIOS trial for AMX0035 in treating Wolfram Syndrome. The trial showed sustained improvements in pancreatic function and stabilization across secondary endpoints. The company plans to proceed with Phase 3 trials and FDA discussions in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:02 pm

AAPL

AMZN

GOOGL

MSFT

QCOM

The EU's NIS 2 cybersecurity directive is now enforceable, requiring companies to enhance cybersecurity or face fines up to $10M. This impacts major tech firms like Apple, Microsoft, Alphabet, Amazon, and Qualcomm, amid broader EU regulatory efforts.

Portfolio Pulse from Pooja Rajkumari

October 17, 2024 | 1:02 pm

DBEU

SPEU

The European Central Bank (ECB) has lowered interest rates by 25 basis points, marking its first back-to-back cuts in 13 years. This decision is part of efforts to manage inflation, which is expected to rise before stabilizing at the 2% target next year. European markets reacted positively, with the Stoxx 600 index rising. Investors are monitoring ETFs like Xtrackers MSCI Europe Hedged Equity ETF (DBEU) and SPDR Portfolio Europe ETF (SPEU) for market reactions.

Portfolio Pulse from Erica Kollmann

October 17, 2024 | 12:55 pm

ELV

Elevance Health has challenged the initial star rating score for one of its larger Medicare Advantage contracts, as discussed in a recent conference call.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:51 pm

ELV

Elevance Health anticipates its 2025 Individual Medicare Advantage membership to grow in line with or slightly better than the broader market. The company is also challenging the initial Star Rating score for one of its larger Medicare Advantage contracts.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:50 pm

SONN

Sonnet BioTherapeutics has regained compliance with Nasdaq's bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:49 pm

KZR

Kezar Life Sciences announced that the PORTOLA trial of zetomipzomib for autoimmune hepatitis will continue without changes, while the PALIZADE trial for lupus nephritis will be discontinued due to safety concerns. The company will focus on developing zetomipzomib for autoimmune hepatitis.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:32 pm

ADIL

Adial Pharmaceuticals has secured a new US patent, expanding its intellectual property protection for its lead drug candidate, AD04, aimed at treating alcohol use disorder. This patent enhances the precision medicine approach by covering additional genotype combinations identified through Adial's genetic diagnostic tool.

Portfolio Pulse from Vandana Singh

October 17, 2024 | 12:30 pm

ADIL

Adial Pharmaceuticals has expanded its patent estate, which covers its unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:30 pm